ADC Therapeutics
ADCT
66 hedge funds and large institutions have $177M invested in ADC Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 12 closing their positions.
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
14% more funds holding
Funds holding: 58 → 66 (+8)
2.79% more ownership
Funds ownership: 44.88% → 47.68% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
36% less capital invested
Capital invested by funds: $274M → $177M (-$97.5M)
57% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 21
69% less call options, than puts
Call options by funds: $75K | Put options by funds: $241K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$17.3M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$5.31M |
| 3 |
Millennium Management
New York
|
+$2.62M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$1.79M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.58M |
| 2 |
GGH
GCM Grosvenor Holdings
Chicago,
Illinois
|
-$4.07M |
| 3 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
-$1.85M |
| 4 |
Walleye Capital
New York
|
-$1.39M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$684K |
ADCT Hedge Fund Activity: Q3 2022 in Review
66 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q3 2022, worth a combined $177M — down 36% from $274M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ADCT positions and 12 closed out — a net gain of 8 holders — while 9 added to existing stakes and 21 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $17.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.58M.
- 66 institutional investors held ADC Therapeutics (ADCT) as of Q3 2022, up from 58 in Q2 2022.
- Funds reported $177M of ADC Therapeutics stock for Q3 2022, down 36% quarter-over-quarter.
- 20 funds opened new ADC Therapeutics positions in Q3 2022 and 12 closed out, a net change of +8 holders.
- The largest ADC Therapeutics buyer in Q3 2022 was Deerfield Management, an estimated $17.3M added.
- The largest ADC Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $5.58M sold.
Based on aggregated 13F filings for Q3 2022.